The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.07
Bid: 1.865
Ask: 2.07
Change: 0.05 (2.48%)
Spread: 0.205 (10.992%)
Open: 2.07
High: 2.07
Low: 2.07
Prev. Close: 2.02
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

Mon, 07th Feb 2022 18:29

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Alphawave IP Group PLC - designs and licences chip technology - Teams with Intel Corp's Intel Foundry Services. Intel Foundry is a unit of Santa Clara, California-based Intel. It manufactures third-party chips. "By combining Intel's manufacturing and operational prowess with Alphawave IP's technology leadership in connectivity solutions, the partnership will enable some of the world's largest chip companies and hyperscalers to build the most advanced semiconductor devices in 2022 and beyond," Alphawave says.

----------

Cadence Minerals PLC - London-based investor in mineral resources - Says required contractual and regulatory documentation completed and filed at Amapa iron ore project, sealing process and ensuring Cadence now owns 20% of the Brazil-based project. Cadence notes Anglo American PLC, a previous owner, valued the asset at USD1.2 billion and impaired it at USD600 million back in its 2012 accounts.

----------

Oilex Ltd - Perth-based company focused on the development of natural gas assets - India's Ministry of Environment, Forest & Climate Change confirms decision to approve environmental clearance for Cambay field.

----------

Hunting PLC - London-based supplier to oil and gas industry - Refinances core borrowing facilities and enters into USD150 million asset based lending facility with Wells Fargo and HSBC. New facility has four-year term and replaces USD160 million revolving credit facility. "The ABL facility contains an accordion feature of up to a further USD50 million which is accessible subject to further credit approval from the relevant lenders, enabling the company to increase the total facility quantum to USD200 million," Hunting adds.

----------

Helium One Global Ltd - London-based exploration & development company - Begins electrical resistivity tomography at Rukwa asset. Survey will probe area identified from phase I and phase II 2D seismic surveys. Will also investigate "surface helium anomalies identified in recently completed multispectral satellite spectroscopy study".

----------

Wildcat Petroleum PLC - targeting investment opportunities in businesses and assets within the upstream sector of the petroleum industry, including the use of blockchain within the sector - Names PETRO-TEC as petroleum consultants. "PT will be able to devise, implement, run and evaluate appropriate field development projects alongside WCAT," company says.

----------

Insig AI PLC - London-based machine learning and data science firm which serves the asset management industry, formerly known as Catena Group PLC - Picked for PwC's Scale FinTech programme, aiming to give access to new opportunities within the accounting firm and its clients. "After an extensive selection process, Insig AI was one of only nine companies this year chosen from more than 700 applicants from around the world. Insig AI is also the only FinTech with ESG expertise on the programme," Insig says.

----------

Octopus Renewables Infrastructure Trust PLC - London-based investment company focused on renewable energy assets in Europe and Australia - Declares 1.25 pence per share dividend for fourth quarter ended December 31. Notes 2021 payout totals 5.0p per share, meeting target. For 2022, it eyes 5.24p payout, up 4.8%.

----------

ImmuPharma PLC - London-based drug discovery and development company - Says UK Medical & Health Products Regulatory Agency approves pharmacokinetic study Lupuzor in Lupus patients. "Volunteers have been selected and approved for inclusion in the PK study," company says. Vounteer dosing to begin on February 15 and study on track to deliver results by end of first quarter.

----------

Ondine Biomedical Inc - Vancouver, Canada-based life sciences company focused on photodisinfection-based therapies - Treats first patients in phase 2 of US Food & Drug Administration nasal photodisinfection exploratory trial. "The study will evaluate how effectively the treatment eradicates pathogens -Staphylococcus aureus - in the nose, and the occurrence of surgical site infections within 30 days of surgery," Ondine adds.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
22 Dec 2016 08:47

ImmuPharma completes patient recruitment in Lupuzor trial

(ShareCast News) - Specialist drug discovery and development company ImmuPharma confirmed on Thursday that patient recruitment had successfully been completed, on target, within the its pivotal Phase III clinical trial of Lupuzor. The AIM-traded firm described Lupuzor as its lead programme for the p

Read more
16 Nov 2016 10:41

ImmuPharma Says Paper Detailing IPP-204106 Mechanism Published

Read more
14 Sep 2016 16:47

ImmuPharma makes positive progress in Lupuzor trials

(ShareCast News) - Specialist drug discovery and development company ImmuPharma updated the market on the progress of its Phase III clinical trial of Lupuzor - its lead programme for the potential breakthrough compound for Lupus - on Wednesday. The AIM-traded firm said it now had a total of 11 sites

Read more
14 Sep 2016 08:45

ImmuPharma Makes Progress With Lupuzor Phase III Trial

Read more
7 Jun 2016 06:59

ImmuPharma Begins Dosing Of European Patients In Lupuzor Trial

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
4 May 2016 09:17

ImmuPharma 2015 Loss Widens As It Focuses On Lupuzor Development

Read more
27 Apr 2016 15:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
9 Mar 2016 10:27

ImmuPharma Begins Patient Recruitment In Europe For Lupuzor Trial

Read more
15 Feb 2016 15:32

ImmuPharma doses first patients in the US

(ShareCast News) - ImmuPharma's clinical expansion into the US reached a significant point on Monday, with the first dosing of patients in its Phase III trial of the in-development lupus treatment Lupuzor. The AIM-traded drug discovery and development company confirmed in a statement that dosing had

Read more
15 Feb 2016 09:02

ImmuPharma Hopeful As US Patients Begin Dosing In Lupus Clinical Trial

Read more
5 Feb 2016 15:26

ImmuPharma to raise £7.5m for 'blockbuster' drug

(ShareCast News) - The 'blockbuster' potential of a drug in development saw ImmuPharma proposing a £7.5m fund raise on Friday. The AIM-traded specialist drug discovery and development company said the deal included a proposed conditional non-preemptive placing of no less than 11,824,877 Placing Shar

Read more
5 Feb 2016 10:32

WINNERS & LOSERS SUMMARY: Just Eat Leaps As It Gobbles Up Takeaways

Read more
5 Feb 2016 08:34

ImmuPharma Looks To Raise Minimum GBP7.5 Million In Equity (ALLISS)

Read more
7 Dec 2015 09:36

ImmuPharma Says US Sites Open For Lupuzor Phase III Trial Recruitment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.